04.11.2021 • NewsNouryon

Nouryon Expands US Levasil Capacity

Nouryon has announced plans to expand capacity for its Levasil colloidal silica at its site in Green Bay, Wisconsin, USA. The expansion will meet rising demand from North America’s construction and packaging sectors. Construction on the facilityis expected to be completed in the second half of 2022.

Patrick Wilhelm, vice president of inorganic specialties, said large governmental infrastructure projects are fueling the demand growth in construction while e-commerce is driving higher demand for packaging materials.

In construction applications, Levasil products provide durability to structures such as bridges and buildings. They are also used to create anti-slip surfaces in packaging applications, making stacking and handling of finished products easier and more efficient.

Nouryon has eight Levasil production plants around the world. It said expansions were ongoing in Sweden and Taiwan, but did not provide further details.

Author: Elaine Burridge, Freelance Journalist

Nouryon has announced plans to expand capacity for its Levasil colloidal silica...
Nouryon has announced plans to expand capacity for its Levasil colloidal silica at its site in Green Bay, Wisconsin, USA. The expansion will meet rising demand from North America’s construction and packaging sectors. Construction should be completed in H2 2022. (c) Nouryon

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.